Literature DB >> 21645284

Neuroprotective effects of tempol acyl esters against retinal ganglion cell death in a rat partial optic nerve crush model.

Sebastian Thaler1, Michal Fiedorowicz, Pawel Grieb, Zbigniew Wypych, Narcyz Knap, Tomasz Borowik, Katarzyna Zawada, Jaroslaw Kaminski, Michal Wozniak, Robert Rejdak, Eberhart Zrenner, Frank Schuettauf.   

Abstract

PURPOSE: The aim of this study is to search for more effective derivatives of the superoxide dismutase mimetic tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl). Although tempol is neuroprotective in a rat partial optic nerve crush (PONC) model, relatively high doses are required to exert this effect.
METHODS: Tempol acyl esters with different-length fatty acids (tempol-C4, tempol-C8, tempol-C12 and tempol-C16) were synthesized and the following properties were evaluated: water-octanol partition coefficient, liposome-liposome energy transfer, and electron paramagnetic resonance (EPR). Brown Norway rats underwent PONC and received tempol or acyl esters intraperitoneally once daily for 7 consecutive days. We then compared the effects of tempol and its four esters on retinal ganglion cell (RGC) damage using a retrograde labelling method.
RESULTS: The water-octanol partition coefficient increased with increasing length of attached acyl chain. However, the energy of the liposome-liposome transfer seemed to be optimal for tempol-C8 and tempol-C12. The EPR signal was very similar for all tested compounds, suggesting similar efficiency of superoxide scavenging. Partial optic nerve crush in vehicle-treated animals reduced RGC numbers by approx. 59% when compared with sham-operated eyes. Tempol did not affect RGC loss at a dose of 1 mg/kg. In contrast, at molar doses equivalent to 1 mg/kg of tempol, tempol-C8 showed a significant neuroprotective effect, whereas tempol-C4, tempol-C12 and tempol-C16 did not act neuroprotectively.
CONCLUSION: Manipulating the hydrophobicity of tempol seems to be a promising tool for developing more potent neuroprotectants in the PONC degeneration model. However, the resulting compounds need further pharmacological evaluation.
© 2011 The Authors. Acta Ophthalmologica © 2011 Acta Ophthalmologica Scandinavica Foundation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21645284     DOI: 10.1111/j.1755-3768.2011.02180.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  5 in total

Review 1.  [Neuroprotective approaches].

Authors:  S Thaler; C Haritoglou; F Schuettauf
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

2.  Rapid repeatable in vivo detection of retinal reactive oxygen species.

Authors:  Ning Fan; Sean M Silverman; Yang Liu; Xizhen Wang; Byung-Jin Kim; Liping Tang; Abbot F Clark; Xuyang Liu; Iok-Hou Pang
Journal:  Exp Eye Res       Date:  2017-06-08       Impact factor: 3.467

3.  Fluorescence probes to detect lipid-derived radicals.

Authors:  Ken-Ichi Yamada; Fumiya Mito; Yuta Matsuoka; Satsuki Ide; Kazushige Shikimachi; Ayano Fujiki; Daiki Kusakabe; Yuma Ishida; Masataka Enoki; Arisa Tada; Miyuki Ariyoshi; Toshihide Yamasaki; Mayumi Yamato
Journal:  Nat Chem Biol       Date:  2016-06-13       Impact factor: 15.040

4.  Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage: Different Dynamics of Changes.

Authors:  Michal Fiedorowicz; Tomasz Choragiewicz; Sebastian Thaler; Frank Schuettauf; Dominika Nowakowska; Kamila Wojtunik; Michele Reibaldi; Teresio Avitabile; Tomasz Kocki; Waldemar A Turski; Agnieszka Kaminska; Pawel Grieb; Eberhart Zrenner; Robert Rejdak; Mario Damiano Toro
Journal:  Front Physiol       Date:  2019-10-01       Impact factor: 4.566

5.  Bioavailability by design - Vitamin D3 liposomal delivery vehicles.

Authors:  Paulina Dałek; Dominik Drabik; Halina Wołczańska; Aleksander Foryś; Małgorzata Jagas; Natalia Jędruchniewicz; Magdalena Przybyło; Wojciech Witkiewicz; Marek Langner
Journal:  Nanomedicine       Date:  2022-03-26       Impact factor: 6.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.